Physician profile
James Brocksmith
NPI 1922061373
$3,151.99
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,549 · 2020: $1,587 · 2021: $15.49.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $645.89 | 2019-2020 | |
| Pfizer INC. | $580.89 | 2019-2020 | |
| Lilly USA, LLC | $328.75 | 2019-2021 | |
| Abbvie INC. | $300.12 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $234.89 | 2019-2020 | |
| Novo Nordisk INC | $183.37 | 2019-2020 | |
| Allergan, INC. | $155.42 | 2019-2020 | |
| Grifols USA, LLC | $145.60 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $121.11 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $84.60 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $59.64 | 2019 | |
| Celgene Corporation | $56.10 | 2019 | |
| Novartis Pharmaceuticals Corporation | $51.14 | 2019 | |
| Supernus Pharmaceuticals, INC. | $48.73 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.68 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $32.31 | 2020 | |
| Amarin Pharma, INC. | $27.00 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $26.18 | 2020 | |
| Astellas Pharma US INC | $22.13 | 2020 | |
| Abbott Laboratories | $14.44 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Brocksmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.